Design, synthesis, biological evaluation, and docking study of 4-isochromanone hybrids bearing N-benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors (part II)
- PMID: 29112799
- DOI: 10.1111/cbdd.13136
Design, synthesis, biological evaluation, and docking study of 4-isochromanone hybrids bearing N-benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors (part II)
Abstract
A series of novel 4-isochromanone compounds bearing N-benzyl pyridinium moiety were designed and synthesized as acetylcholinesterase (AChE) inhibitors. The biological evaluation showed that most of the target compounds exhibited potent inhibitory activities against AChE. Among them, compound 1q possessed the strongest anti-AChE activity with an IC50 value of 0.15 nm and high AChE/BuChE selectivity (SI > 5,000). Moreover, compound 1q had low toxicity in normal nerve cells and was relatively stable in rat plasma. Together, the current finding may provide a new approach for the discovery of novel anti-Alzheimer's disease agents.
Keywords: 4-isochromanone skeleton; Alzheimer's disease; acetylcholinesterase inhibitors; benzyl pyridine.
© 2017 John Wiley & Sons A/S.
Similar articles
-
Design, synthesis, biological evaluation and docking study of 4-isochromanone hybrids bearing N-benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors.Bioorg Med Chem Lett. 2015 Nov 15;25(22):5212-6. doi: 10.1016/j.bmcl.2015.09.063. Epub 2015 Sep 28. Bioorg Med Chem Lett. 2015. PMID: 26454504
-
Design, synthesis and biological evaluation of edaravone derivatives bearing the N-benzyl pyridinium moiety as multifunctional anti-Alzheimer's agents.J Enzyme Inhib Med Chem. 2020 Dec;35(1):1596-1605. doi: 10.1080/14756366.2020.1801673. J Enzyme Inhib Med Chem. 2020. PMID: 32779503 Free PMC article.
-
New benzyl pyridinium derivatives bearing 2,4-dioxochroman moiety as potent agents for treatment of Alzheimer's disease: Design, synthesis, biological evaluation, and docking study.Bioorg Chem. 2019 Jun;87:506-515. doi: 10.1016/j.bioorg.2019.03.012. Epub 2019 Mar 6. Bioorg Chem. 2019. PMID: 30928873
-
Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter.Chem Pharm Bull (Tokyo). 2010 Mar;58(3):273-87. doi: 10.1248/cpb.58.273. Chem Pharm Bull (Tokyo). 2010. PMID: 20190429 Review.
-
Acetylcholinesterase: The "Hub" for Neurodegenerative Diseases and Chemical Weapons Convention.Biomolecules. 2020 Mar 7;10(3):414. doi: 10.3390/biom10030414. Biomolecules. 2020. PMID: 32155996 Free PMC article. Review.
Cited by
-
Straightforward Synthesis of Bis[(trifluoromethyl)sulfonyl]ethylated Isocoumarins from 2-Ethynylbenzoates.J Org Chem. 2023 Jun 2;88(11):7373-7380. doi: 10.1021/acs.joc.3c00611. Epub 2023 May 3. J Org Chem. 2023. PMID: 37133251 Free PMC article.
-
Development of p-Tau Differentiated Cell Model of Alzheimer's Disease to Screen Novel Acetylcholinesterase Inhibitors.Int J Mol Sci. 2022 Nov 26;23(23):14794. doi: 10.3390/ijms232314794. Int J Mol Sci. 2022. PMID: 36499118 Free PMC article.
-
Novel and Potent Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease from Natural (±)-7,8-Dihydroxy-3-methyl-isochroman-4-one.Molecules. 2022 May 11;27(10):3090. doi: 10.3390/molecules27103090. Molecules. 2022. PMID: 35630563 Free PMC article.
-
In vivo Evaluation of a Newly Synthesized Acetylcholinesterase Inhibitor in a Transgenic Drosophila Model of Alzheimer's Disease.Front Neurosci. 2021 Jun 30;15:691222. doi: 10.3389/fnins.2021.691222. eCollection 2021. Front Neurosci. 2021. PMID: 34276297 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
